Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20877908 | 0.81 | PPARA (0.43) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL16559310 | 0.81 | PPARA (0.43) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL3110938 | 0.81 | L3MBTL1 (0.49) | NPC1PPARACTSSPPARGCA12 | |
| SCHEMBL4545478 | 0.78 | PPARA (0.48) | NPC1RAB9ASMN1; SMN2PPARACTSS | |
| SCHEMBL7131218 | 0.78 | PPARA (0.51) | NPC1MEN1KMT2APPARACTSS | |
| SCHEMBL10736434 | 0.77 | SYK (0.53) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL716007 | 0.76 | NPC1 (0.56) | NPC1RAB9APPARACTSSPPARG | |
| SCHEMBL18601225 | 0.76 | PPARA (0.46) | NPC1RAB9ASMN1; SMN2PPARACTSS | |
| SCHEMBL27525177 | 0.76 | PPARA (0.55) | PPARACTSSPPARGCA12CA1 | |
| SCHEMBL18490885 | 0.75 | PPARA (0.54) | NPC1RAB9AMEN1KMT2APPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790836-B2 | Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| EP-1258490-B1 | PROCESS FOR PREPARING INDOLOPYRROLOCARBAZOLE DERIVATIVES, INTERMEDIATES THEREOF, AND PREPARATION PROCESS OF THE INTERMEDIATES | BANYU PHARMA CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030060621-A1 | Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1258490-A1 | PROCESS FOR PREPARING INDOLOPYRROLOCARBAZOLE DERIVATIVES, INTERMEDIATES THEREFOR, AND PREPARATION PROCESS OF THE INTERMEDIATES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060621-A1 | Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates | WEE1, CYP4B1, CYP3A4 | NPC1 4437/4885RAB9A 3083/4885SMN1; SMN2 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.